The findings confirm that NSCLC cells diverge towards CB-839 either sensitive or resistant phenotypes, with no distinction between NSCLC cells with KRAS mutations or LKB1 loss either in single or concomitant genetic lesions. This evidence concerns the gene KRAS and non-small cell lung carcinoma.